AwardTape · Defense awards · Research and development · Defense systems R&D · HDTRA120C0045
HDTRA120C0045: $2.3M definitive contract to Synergene Therapeutics Inc
Synergene Therapeutics Inc holds a definitive contract from Defense Threat Reduction Agency with $2.3M obligated since Oct 2023 and $7.6M obligated over its life, against a ceiling of $12.2M. Latest action Feb 11, 2025.
Application of a nanocomplex technology to the active permeation of the blood brain barrier (bbb)
| PIID | HDTRA120C0045 |
|---|---|
| Type | definitive contract |
| Company | Synergene Therapeutics Inc |
| Agency | Defense Threat Reduction Agency |
| Contracting office | DEFENSE THREAT REDUCTION AGENCY |
| Category | Research and development · Defense systems R&D |
| PSC | AD92 R&D- DEFENSE OTHER: OTHER (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT) |
| NAICS | 541714 RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) |
| Obligated since Oct 2023 | $2.3M |
| Total obligated (lifetime) | $7.6M |
| Ceiling (base and all options) | $12.2M |
| Base date | Jul 7, 2020 |
| Latest action | Feb 11, 2025 |
| End date | Jul 6, 2025 |
| Actions since Oct 2023 | 5 |
| Pricing | Cost plus fixed fee |
| Competition | Competed after exclusion of sources |
| Place of performance | MD |
| Source | USAspending.gov record |
| Reporting lag | DoD 90 days |
Source: USAspending.gov prime award data (FPDS), DoD and DHS contracts, orders and IDVs with any action since Oct 1, 2023. Obligated FY2024+ sums the obligations on those actions; total obligated is the award's lifetime figure. DoD contract actions publish on USAspending about 90 days after signing (DFARS PGI 204.6), so the latest DoD actions here trail the calendar by about 3 months. Place of performance shows the state only.
Terminal: alerts on new orders and modifications to this contract, and CSV export.
7 days free for first-time subscribers, then $49/mo. Card required. Cancel before day 8 and you pay nothing.
Start free trial